Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543526 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL3102542 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL3102552 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL8432621 | 1.00 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8529468 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL29907288 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8529474 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8533298 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8545811 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL17105739 | 0.98 | TACR1 (0.97) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| US-11426384-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (Trading as Pressure Neuro) (AU) | 2022-08-30 | — | — | US | claimed |
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | claimed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | claimed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | claimed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | claimed |
| EP-3846811-B1 | COMBINATION OF APREPITANT, BUPIVACAINE, AND MELOXICAM FOR USE IN THE TREATMENT OF POST-SURGICAL PAIN | HERON THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | disclosed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | TACR1 34/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | TACR1 1/4885 |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | GPR88, GPR65, ARRB1 | TACR1 250/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.